Am I a Candidate for Medical Weight-Loss Treatment?
Discover which medical criteria determine whether you may benefit from pharmacological treatment for obesity or overweight, and what you should know before taking the next step.
More and more people are asking whether there is a medical treatment that can help them lose weight effectively and safely.
The answer is yes, but not for everyone and not under all circumstances.
The new generation of weight-management medications—particularly GLP-1 receptor agonists such as semaglutide and dual GIP/GLP-1 receptor agonists such as tirzepatide—has transformed the medical treatment of obesity.
However, these medications are prescribed according to specific clinical criteria that should be understood before considering treatment.
Obesity Is a Disease, Not a Choice
For decades, obesity was often understood as a direct consequence of a lack of willpower or poor lifestyle habits.
Current scientific evidence has radically changed this view.
Obesity is now recognised by leading international medical organisations as a chronic, complex and relapsing disease involving metabolic, hormonal and neurological changes that make weight management difficult through lifestyle measures alone.
This change in perspective is important because it directly affects how obesity is treated.
Just as high blood pressure or diabetes may require medication, obesity may also require pharmacological treatment when the health risk is significant and other measures have not been sufficient.
What Criteria Determine Whether I Am a Candidate?
The indication for pharmacological weight-management treatment is not based simply on the desire to lose weight.
It is based on objective clinical criteria.
In general, treatments approved in Europe for this purpose, including semaglutide 2.4 mg and tirzepatide at doses used for obesity, are indicated in adults who meet one of the following criteria.
Body Mass Index of 30 kg/m² or Higher
This is the standard threshold for obesity.
In this situation, pharmacological treatment may be considered when lifestyle changes have not been sufficient to achieve clinically meaningful weight loss.
Body Mass Index of 27 kg/m² or Higher with at Least One Weight-Related Complication
In this case, the threshold is lower because the presence of associated health conditions significantly increases cardiometabolic risk.
Commonly recognised complications include:
High blood pressure.
Dyslipidaemia, including elevated cholesterol or triglycerides.
Type 2 diabetes or prediabetes.
Established cardiovascular disease.
Obstructive sleep apnoea.
Non-alcoholic steatohepatitis, meaning fatty liver disease with inflammation.
What Does BMI Mean and How Is It Calculated?
Body mass index, or BMI, is a simple measurement that relates weight to height.
It is calculated by dividing weight in kilograms by height in metres squared.
For example, a person who weighs 90 kg and is 1.70 metres tall would have a BMI of 31.1 kg/m², which is classified as class I obesity.
It is important to understand that BMI is useful but not perfect.
It does not distinguish between muscle mass and body fat, and it does not account for fat distribution, which also influences cardiometabolic risk.
For this reason, a clinical assessment also considers other factors, including:
Waist circumference.
Blood test results.
Medical history.
What If I Am Overweight but Do Not Meet the Obesity Threshold?
There is an intermediate category that deserves particular attention: patients with a BMI between 25 and 27 kg/m², meaning overweight without reaching the obesity threshold, and without clearly established comorbidities.
In this group, GLP-1 medications do not have a formal indication in their European product information for weight management.
However, in international clinical practice, particularly in countries such as the United States where pharmacological obesity treatment has been used more extensively for several years, off-label prescribing is becoming more common.
Off-label use means prescribing a medication outside its formally approved indication.
This may be considered in patients with overweight who have not responded to lifestyle measures or who present metabolic risk factors that do not meet the strict definition of a comorbidity.
This approach always requires:
An individual medical assessment.
An informed decision by the patient.
Close clinical follow-up.
It is not appropriate for everyone, but it is a real possibility that a doctor may consider when the balance of benefits and risks justifies it.
In Europe, and particularly in Spain, this approach is generally more conservative and should be assessed cautiously on a case-by-case basis.
The final decision must always be made by a doctor following a complete evaluation.
Beyond the Scales: Emotional Wellbeing Also Matters
Reducing weight management to a purely medical or cosmetic issue oversimplifies a much more complex reality.
Feeling comfortable in your own body and reaching a weight at which you recognise yourself and feel well can have a real impact on:
Mental health.
Self-esteem.
Social relationships.
Overall quality of life.
Scientific evidence supports this dimension.
Patients who achieve sustained weight loss, particularly when supported by appropriate medical follow-up, often experience meaningful improvements in:
Body image.
Mood.
Depressive symptoms associated with obesity.
Energy levels.
Personal confidence.
The psychological and social benefits are not minor side effects.
For many patients, they are among the most transformative aspects of treatment.
This does not mean that pharmacological treatment is appropriate for anyone who wishes to improve their appearance.
It does mean that, in patients with a medical indication, emotional wellbeing and self-esteem are legitimate treatment goals alongside cardiometabolic health.
Who Should Not Receive This Type of Treatment?
There are clear contraindications that must be assessed before any prescription is issued.
In general, these treatments are not indicated in the following situations:
Pregnancy.
Recent breastfeeding, particularly within the previous six months.
A personal or family history of medullary thyroid carcinoma.
Multiple endocrine neoplasia syndrome type 2, or MEN2.
Active pancreatitis.
A history of severe pancreatitis.
A known allergy to the active ingredient or any of the excipients.
In addition, the decision must be individualised in patients with certain gastrointestinal conditions, advanced kidney disease or other relevant medical problems.
In these cases, the doctor may advise against treatment or modify the approach.
Does My Reason for Wanting to Lose Weight Matter?
Yes, and it is important to understand why.
Pharmacological treatments for weight management are approved for specific medical indications, not for purely cosmetic purposes in people without health-related risk.
This does not mean that only people with severe obesity may be candidates.
It does mean that treatment must respond to health-related criteria and be assessed by a doctor.
The patient’s motivation still matters in another way.
Pharmacological treatment is more likely to be effective and sustainable when it is combined with meaningful changes in diet and physical activity and when ongoing medical follow-up is provided.
Health, self-esteem and wellbeing can coexist as goals and reinforce one another.
What Happens During the Assessment Consultation?
Before starting treatment, the doctor carries out a complete clinical assessment.
This usually includes:
Detailed Medical History
Previous medical conditions.
Current medication.
Previous weight-loss attempts.
Physical Assessment
Weight.
Height.
BMI.
Waist circumference.
Blood pressure.
Heart rate.
Review or Request for Blood Tests
These may include:
Blood glucose.
Lipid profile.
Liver function.
Kidney function.
Thyroid function.
Other parameters depending on the patient’s circumstances.
Electrocardiogram When Clinically Indicated
This is particularly relevant in patients with cardiovascular risk factors.
Assessment of Contraindications and Potential Drug Interactions
Using all this information, the doctor can determine:
Whether pharmacological treatment is indicated.
Which medication is most appropriate.
What starting dose should be used.
What follow-up plan is required.
What Role Do Lifestyle Habits Play?
Pharmacological treatment does not replace healthy eating or physical activity.
It complements them.
Current clinical guidelines are clear on this point.
The greatest benefit is achieved when medication is used as part of a comprehensive approach that includes lifestyle changes and medical follow-up.
When treatment is discontinued, some of the weight lost may be regained if sustainable habits have not been established in areas such as:
Diet.
Exercise.
Sleep.
Stress management.
Other daily routines.
Lifestyle work is therefore not optional.
It is an essential part of treatment.
How Long Does Treatment Last?
Obesity is a chronic disease, and treatment is often long term.
There is no single standard treatment period that applies to every patient.
In many cases, treatment is continued while:
A medical indication remains.
The patient is responding well.
The medication is tolerated.
The balance of benefits and risks remains favourable.
This does not mean that treatment must continue for life in every case.
However, the decision to maintain or discontinue it should be made with a doctor rather than independently, as stopping treatment may affect weight maintenance.
Is There a Rebound Effect After Stopping Treatment?
This is one of the most common concerns, and it should be addressed clearly.
Yes, there is a risk of regaining some of the weight lost after pharmacological treatment is discontinued.
The available scientific evidence is consistent on this point, and patients should understand it before starting a programme.
The STEP 1 extension study, published in Diabetes, Obesity and Metabolism, assessed what happened after patients discontinued semaglutide 2.4 mg following 68 weeks of treatment.
One year after stopping treatment, participants had regained approximately two-thirds of the weight they had lost.
Similar findings have been reported with tirzepatide in the SURMOUNT-4 trial, where discontinuation was associated with significant weight regain over the following months.
This does not mean that treatment does not work.
It means that obesity is a chronic disease with a strong biological basis, including changes in:
Hormonal regulation.
Metabolism.
Appetite control.
These mechanisms may reappear when the treatment controlling them is removed.
The same principle applies to conditions such as high blood pressure or type 2 diabetes.
When medication is stopped without resolving the underlying condition, the affected parameters may worsen again.
How Can the Risk of Weight Regain Be Reduced?
Evidence suggests that several factors may help reduce weight regain after medication is discontinued.
Establishing Habits During Treatment
This includes:
A balanced diet.
Regular physical activity.
Adequate sleep.
Stress management.
Gradual Dose Reduction Under Medical Supervision
A gradual reduction may be preferable to stopping treatment abruptly in selected patients.
Continued Medical Follow-Up After Discontinuation
This may include:
Regular weight checks.
Reinforcement of lifestyle habits.
Early intervention if weight regain begins.
Long-Term Treatment at a Lower Dose in Selected Patients
For some patients, continued treatment at a lower dose may be considered when the balance of benefits and risks supports it.
An Honest Conversation with Your Doctor
Before starting treatment, it is important to discuss:
The expected duration.
Realistic goals.
The long-term maintenance plan.
For many patients, the most useful question is not simply, “How long will I take the medication?”
A better question is, “How can I build a sustainable plan that combines treatment, lifestyle changes and follow-up to maintain the results over time?”
Recognising obesity as a chronic disease helps explain why treatment may need to continue over the longer term, just as it does with other chronic conditions.
The good news is that, with appropriate follow-up, results can be maintained and the benefits for cardiometabolic health and emotional wellbeing can continue over time.
What Results Can I Expect?
Clinical trials involving current medications have shown significant average weight loss.
However, these figures should be interpreted realistically.
Results vary between individuals depending on factors such as:
Starting weight.
Adherence to treatment.
Lifestyle habits.
Individual response to the medication.
Weight loss is also not the only relevant outcome.
In many patients, treatment can improve cardiometabolic parameters, including:
Blood glucose.
Blood pressure.
Lipid profile.
Cardiac function.
These improvements may reduce cardiovascular risk beyond the number shown on the scales.
Many patients also report improvements in:
Self-esteem.
Psychosocial wellbeing.
Quality of life.
For some people, these benefits are just as important as the clinical data.
Frequently Asked Questions
Can I Start Treatment Without Seeing a Doctor?
No.
All weight-management medications require a prescription and a prior medical assessment.
Obtaining them without a prescription or through unregulated channels carries significant health risks.
Can I Be a Candidate Without Any Associated Medical Conditions?
If your BMI is 30 kg/m² or higher and lifestyle changes have not been sufficient, pharmacological treatment may be indicated even when no comorbidities are present.
For people with a BMI between 25 and 27 kg/m², the decision depends on an individual medical assessment and the balance of benefits and risks.
Do I Need Blood Tests Before Starting?
In most cases, yes.
Baseline blood tests help:
Rule out contraindications.
Assess cardiometabolic risk.
Provide a reference point for future monitoring.
Is Treatment Covered by the Spanish Public Healthcare System?
At the time of publication, medications approved specifically for weight management in adults with obesity are not generally funded by Spain’s National Health System.
This may change in the future, so it is advisable to discuss the current situation with your doctor or consult the relevant information for your autonomous community.
Final Message
If you are wondering whether you are a candidate for medical weight-loss treatment, the first step is always to consult a doctor.
Obesity and overweight associated with cardiometabolic risk deserve a serious, individualised and evidence-based approach, not quick fixes or unsupervised treatment.
At DomoMed Salud, we are committed to providing accessible, rigorous medical care based on the best available evidence.
Our goal is to offer clear information and high-quality medical support to help you protect your health and the health of your loved ones.
We care about both cardiometabolic health and emotional wellbeing because feeling better in your body and improving your health go hand in hand.
Thank you for trusting DomoMed Salud.
The DomoMed Salud Team
Bibliography Note
Prepared in April 2026.
This content was developed using:
The European product information for Wegovy, containing semaglutide 2.4 mg.
The European product information for Mounjaro, containing tirzepatide.
Therapeutic frameworks from the European Association for the Study of Obesity.
Guidelines from the Spanish Society for the Study of Obesity.
Reference materials from the National Heart, Lung, and Blood Institute.
Reference materials from the American Heart Association.
The findings on weight regain after treatment discontinuation were based on:
The STEP 1 extension study published in Diabetes, Obesity and Metabolism.
The SURMOUNT-4 trial involving tirzepatide.
Related publications on treatment adherence and long-term maintenance in the pharmacological management of obesity.
Medical Disclaimer
The information contained in this article is intended for informational and educational purposes only.
It does not replace an individual medical assessment.
Off-label prescribing must always be assessed by a doctor, with the patient’s informed consent and close clinical follow-up.
If you have concerns about your weight, cardiometabolic risk or whether pharmacological treatment is appropriate for you, consult your doctor for a personalised assessment.
